ALNYLAM PHARMACEUTICALS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Cash and Cash Equivalents, Period Increase (Decrease) of $451.74 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-02-15
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $443.32M, a 1663.67% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$206.63M.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was $237.59M, a 496.99% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$22.54M, a 144.73% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $451.74M, a 3450.89% increase from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $12.72M, a 87.97% decline from fiscal 2015.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was $105.72M, a 380.31% increase from fiscal 2014.
- ALNYLAM PHARMACEUTICALS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $22.01M, a 1147.73% increase from fiscal 2013.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $443.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $236.69M derived: sum of 2 quarters · filed 2018-02-15 | $474.28M derived: sum of 3 quarters · filed 2018-02-15 | $451.74M 10-K · filed 2018-02-15 |
| 2017-09-30 | -$206.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $30.97M derived: sum of 2 quarters · filed 2017-11-07 | $8.43M 10-Q · filed 2017-11-07 | $33.56M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-06-30 | $237.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $215.05M 10-Q · filed 2017-08-09 | $240.19M derived: sum of 3 quarters · filed 2018-02-15 | $137.59M derived: sum of 4 quarters · filed 2018-02-15 |
| 2017-03-31 | -$22.54M 10-Q · filed 2017-05-05 | $2.60M derived: sum of 2 quarters · filed 2018-02-15 | -$100.00M derived: sum of 3 quarters · filed 2018-02-15 | -$60.20M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-12-31 | $25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$77.46M derived: sum of 2 quarters · filed 2018-02-15 | -$37.66M derived: sum of 3 quarters · filed 2018-02-15 | $12.72M 10-K · filed 2018-02-15 |
| 2016-09-30 | -$102.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$62.80M derived: sum of 2 quarters · filed 2017-11-07 | -$12.41M 10-Q · filed 2017-11-07 | $19.26M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $39.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $90.18M 10-Q · filed 2017-08-09 | $121.86M derived: sum of 3 quarters · filed 2018-02-15 | $119.81M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $50.38M 10-Q · filed 2017-05-05 | $82.06M derived: sum of 2 quarters · filed 2018-02-15 | $80.02M derived: sum of 3 quarters · filed 2018-02-15 | -$75.30M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $31.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $29.63M derived: sum of 2 quarters · filed 2018-02-15 | -$125.69M derived: sum of 3 quarters · filed 2018-02-15 | $105.72M 10-K · filed 2018-02-15 |
| 2015-09-30 | -$2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$157.36M derived: sum of 2 quarters · filed 2016-11-03 | $74.04M 10-Q · filed 2016-11-03 | $66.50M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | -$155.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $76.08M 10-Q · filed 2016-08-04 | $68.54M derived: sum of 3 quarters · filed 2017-02-15 | $70.53M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $231.40M 10-Q · filed 2016-05-04 | $223.86M derived: sum of 2 quarters · filed 2017-02-15 | $225.85M derived: sum of 3 quarters · filed 2017-02-15 | -$44.01M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | -$7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | -$5.55M derived: sum of 2 quarters · filed 2017-02-15 | -$275.41M derived: sum of 3 quarters · filed 2017-02-15 | $22.01M 10-K · filed 2017-02-15 |
| 2014-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | -$267.87M derived: sum of 2 quarters · filed 2015-11-09 | $29.55M 10-Q · filed 2015-11-09 | $70.88M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | -$269.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $27.56M 10-Q · filed 2015-08-07 | $68.89M derived: sum of 3 quarters · filed 2016-02-12 | $55.75M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $297.42M 10-Q · filed 2015-05-08 | $338.75M derived: sum of 2 quarters · filed 2016-02-12 | $325.61M derived: sum of 3 quarters · filed 2016-02-12 | $252.78M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $41.33M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $28.19M derived: sum of 2 quarters · filed 2016-02-12 | -$44.63M derived: sum of 3 quarters · filed 2016-02-12 | $1.76M 10-K · filed 2016-02-12 |
| 2013-09-30 | -$13.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$85.96M derived: sum of 2 quarters · filed 2014-11-06 | -$39.56M 10-Q · filed 2014-11-06 | -$64.00M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | -$72.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$26.43M 10-Q · filed 2014-08-08 | -$50.86M derived: sum of 3 quarters · filed 2015-02-13 | -$23.30M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $46.40M 10-Q · filed 2014-05-09 | $21.97M derived: sum of 2 quarters · filed 2015-02-13 | $49.53M derived: sum of 3 quarters · filed 2015-02-13 | $36.06M derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | -$24.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $3.13M derived: sum of 2 quarters · filed 2015-02-13 | -$10.33M derived: sum of 3 quarters · filed 2015-02-13 | -$18.82M 10-K · filed 2015-02-13 |
| 2012-09-30 | $27.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $14.10M derived: sum of 2 quarters · filed 2013-11-07 | $5.61M 10-Q · filed 2013-11-07 | $1.50M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-06-30 | -$13.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$21.95M 10-Q · filed 2013-08-09 | -$26.06M derived: sum of 3 quarters · filed 2014-02-20 | -$18.84M derived: sum of 4 quarters · filed 2014-02-20 |
| 2012-03-31 | -$8.49M 10-Q · filed 2013-05-07 | -$12.60M derived: sum of 2 quarters · filed 2014-02-20 | -$5.37M derived: sum of 3 quarters · filed 2014-02-20 | -$28.85M derived: sum of 4 quarters · filed 2014-02-20 |
| 2011-12-31 | -$4.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-20 | $3.12M derived: sum of 2 quarters · filed 2014-02-20 | -$20.36M derived: sum of 3 quarters · filed 2014-02-20 | -$4.37M 10-K · filed 2014-02-20 |
| 2011-09-30 | $7.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-05 | -$16.25M derived: sum of 2 quarters · filed 2012-11-05 | -$263.00K 10-Q · filed 2012-11-05 | $27.45M derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-06-30 | -$23.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$7.49M 10-Q · filed 2012-08-08 | $20.23M derived: sum of 3 quarters · filed 2013-02-19 | $928.00K derived: sum of 4 quarters · filed 2013-02-19 |
| 2011-03-31 | $15.99M 10-Q · filed 2012-05-03 | $43.71M derived: sum of 2 quarters · filed 2013-02-19 | $24.41M derived: sum of 3 quarters · filed 2013-02-19 | -$24.36M derived: sum of 4 quarters · filed 2013-02-19 |
| 2010-12-31 | $27.72M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-19 | $8.42M derived: sum of 2 quarters · filed 2013-02-19 | -$40.35M derived: sum of 3 quarters · filed 2013-02-19 | -$62.87M 10-K · filed 2013-02-19 |
| 2010-09-30 | -$19.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03 | -$68.07M derived: sum of 2 quarters · filed 2011-11-03 | -$90.59M 10-Q · filed 2011-11-03 | -$51.21M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-06-30 | -$48.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | -$71.29M 10-Q · filed 2011-08-03 | -$31.91M derived: sum of 3 quarters · filed 2012-02-13 | -$81.69M derived: sum of 4 quarters · filed 2012-02-13 |
| 2010-03-31 | -$22.52M 10-Q · filed 2011-05-05 | $16.86M derived: sum of 2 quarters · filed 2012-02-13 | -$32.92M derived: sum of 3 quarters · filed 2012-02-13 | |
| 2009-12-31 | $39.38M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-13 | -$10.40M derived: sum of 2 quarters · filed 2012-02-13 | -$54.32M 10-K · filed 2012-02-13 | |
| 2009-09-30 | -$49.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-04 | -$93.70M 10-Q · filed 2010-11-04 | ||
| 2009-06-30 | -$43.92M 10-Q · filed 2010-08-05 | |||
| 2008-12-31 | $86.64M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |